Targeted Early Treatment With ALK's ACARIZAX® Could Improve Allergic Asthma Treatment, Allergy Congress Hears

- Easy to measure biomarkers could identify a group of patients
who benefit even more from ACARIZAX® treatment of house dust mite
(HDM)-induced allergic asthma

- Early identification of patients would allow earlier treatment
intervention

- With its HDM SLIT-tablet, ALK is well-placed to lead the way on
personalized treatment of allergic asthma

Hørsholm, Denmark (ots/PRNewswire) - ALK's (ALKB:DC / OMX: ALK B /
AKABY / AKBLF) sublingual allergy immunotherapy (SLIT) tablet against
house dust mite (HDM) allergy ought to have a greater role to play in
the treatment of allergic asthma, the Annual Congress of the European
Academy of Allergy and Clinical Immunology (EAACI) heard today.

Easy to measure blood biomarkers, such as blood eosinophils and
total immunoglobulin E (IgE) used to guide treatment with other
asthma biologic treatments, identifies patients most at risk of
asthma exacerbations.

The findings were presented at an ALK-sponsored symposium on
'using biomarkers in allergic asthma to predict patient responses to
treatment with allergy immunotherapy'. Biomarkers are biological
indicators of disease or treatment effect, and commonly used in
several other conditions, including heart disease and diabetes.

Eugene Bleecker, MD, Professor of Medicine, University of Arizona,
said, "Biomarkers can play an important role allowing us to identify
the most susceptible allergic asthma patients, and permitting
clinicians to make better treatment decisions. These data show that
the rationale for targeted biologics treatment in asthma, also
applies to the HDM SLIT-tablet."

ALK's HDM SLIT-tablet is the only treatment option targeting the
underlying cause of the disease in HDM allergic asthma.

Henrik Jacobi, Executive Vice President of R&D, ALK, said, "We
already know that ACARIZAX® provides medical benefit in the treatment
of HDM-induced allergic asthma. We now have evidence that ACARIZAX®
targets the same immunological pathways, as documented by anti-IgE
and anti-inteleukin-5 biologic treatments."

Nearly all patients with HDM-induced allergic asthma have
concomitant HDM-induced allergic rhinitis, and ACARIZAX® is also
documented to provide benefits in this condition.

ALK-Abelló A/S

About ALK

ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs
around 2,300 people worldwide and is listed on Nasdaq Copenhagen.
Find more information at www.alk.net.

ots Originaltext: ALK
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Per Plotnikof
tel. +45-4574-7527
mobile +45-2261-2525 Media: Jeppe Ilkjær
tel. +45-7877-4532
mobile +45-3050-2014

Original-Content von: ALK, übermittelt durch news aktuell